Please assess the completion status of the following clinical trial:

Trial Title: Steroids In Eosinophil Negative Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Physician-diagnosed asthma for at least previous 12 months.~* Able to perform reproducible spirometry.~* Baseline FEV1≥70% of predicted.~* Asthma confirmed either by:~  * Beta-agonist reversibility to 4 puffs albuterol ≥ 12% OR~ * Methacholine PC20 ≤ 16 mg/ml~* At least 1 of the following indications for chronic controller therapy:~  * Asthma Symptoms \> 2 days/week OR~ * Nocturnal Asthma Symptoms \> 2 nights/month OR~ * Short-acting beta-agonist use for symptom control \> 2 days/week~* For participants ≥18 years of age: Ability to provide informed consent. For participants under 18 years of age: Ability to provide verbal or written assent and ability of parent to provide informed consent.~* Willingness, if female and able to conceive, to utilize one medically-acceptable form of contraception.~Exclusion Criteria:~* Chronic inhaled or oral corticosteroid therapy.~* Use of inhaled or oral corticosteroid therapy within 6 weeks.~* New allergen immunotherapy within the past 3 months or anticipated changes to an ongoing immunotherapy regimen.~* Use of omalizumab within 3 months.~* History of:~  * bladder-neck obstruction, urinary retention or benign prostatic hyperplasia~ * narrow angle glaucoma~ * significant cardiovascular disorders and arrhythmias~ * life-threatening asthma requiring treatment with intubation or mechanical ventilation within the past 5 years~* Respiratory tract infection within past 6 weeks.~* History of smoking within the past 1 year, or \> 10 pack-years total if ≥ 18 years of age, or \> 5 pack-years total if \< 18 years of age.~* Chronic diseases or medical conditions (other than asthma) that could put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system, or immunodeficiency.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone then Tiotropium then Placebo (Type: EXPERIMENTAL): Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
- Mometasone then Placebo then Tiotropium (Type: EXPERIMENTAL): Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
- Placebo then Mometasone then Tiotropium (Type: EXPERIMENTAL): Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
- Placebo then Tiotropium then Mometasone (Type: EXPERIMENTAL): Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
- Tiotropium then Placebo then Mometasone (Type: EXPERIMENTAL): Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
- Tiotropium then Mometasone then Placebo (Type: EXPERIMENTAL): Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).